StemCells (STEM -1%) announces the publication of two papers reporting positive clinical and...

|By:, SA News Editor

StemCells (STEM -1%) announces the publication of two papers reporting positive clinical and preclinical data of its proprietary HuCNS-SC cells, used for a range of myelination disorders, were published in the October 10 edition of Science Translational Medicine. The papers outline Phase I clinical trials on Pelizaeus-Merzbacher disease, a genetic disorder that afflicts children, and data on the transplantation of neural stem cells in an animal with severe myelin deficiency which resulted in in new myelin, thus enhancing the conductivity of nerve impulses.